Milligan Sandra
SEC CIK 1859810 · EDGAR
BoughtSold
Most active insiders at GOSS, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Smith Robert Paul JR | Chief Commercial Off | — | — |
| 2 | Aranda Richard | Chief Medical Off | — | — |
| 3 | Peterson Caryn | EVP, Regulatory Affairs | — | — |
| 4 | Giraudo Bryan | COO, CFO | — | — |
| 5 | Christian Waage | EVP, Tech Ops, Admin | — | — |
| 6 | Hasnain Faheem | Pres, CEO, Dir | — | — |
Milligan Sandra made no open-market trades at GOSS in the last 12 months.
Transactions 16
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-08-20 | 2025-08-19 | GOSS | Gossamer Bio, Inc. | Milligan Sandra | Dir | P - Purchase | $1.92 | +26.1K | 58.0K | +81% | +$50.0K | |
| I | 2023-11-17 | 2023-11-15 | GOSS | Gossamer Bio, Inc. | Milligan Sandra | Dir | P - Purchase | $0.79 | +32.0K | 32.0K | New | +$25.3K |
| D | 2023-05-08 | 2023-05-04 | OGN | Organon & Co. | Milligan Sandra | Head of Research, Development | F - Tax | $24.24 | -2,168 | 28.6K | -7% | -$52.6K |
| D | 2023-05-08 | 2023-05-04 | OGN | Organon & Co. | Milligan Sandra | Head of Research, Development | M - OptEx | — | +4,984 | 30.8K | +19% | — |
| D | 2023-05-03 | 2023-05-01 | OGN | Organon & Co. | Milligan Sandra | Head of Research, Development | M - OptEx | — | +1,899 | 26.6K | +8% | — |
| D | 2023-05-03 | 2023-05-01 | OGN | Organon & Co. | Milligan Sandra | Head of Research, Development | F - Tax | $24.63 | -826 | 25.8K | -3% | -$20.3K |
| D | 2023-04-04 | 2023-03-31 | OGN | Organon & Co. | Milligan Sandra | Head of Research, Development | F - Tax | $23.09 | -2,115 | 24.7K | -8% | -$48.8K |
| D | 2023-04-04 | 2023-03-31 | OGN | Organon & Co. | Milligan Sandra | Head of Research, Development | M - OptEx | $0.00 | +5,964 | 26.8K | +29% | $0 |
| D | 2023-03-02 | 2023-02-28 | OGN | Organon & Co. | Milligan Sandra | Head of Research, Development | M - OptEx | — | +7,976 | 23.2K | +52% | — |
| D | 2023-03-02 | 2023-02-28 | OGN | Organon & Co. | Milligan Sandra | Head of Research, Development | F - Tax | $25.09 | -2,346 | 20.9K | -10% | -$58.9K |
| DM | 2022-05-05 | 2022-05-03+ | OGN | Organon & Co. | Milligan Sandra | Head of Research, Development | M - OptEx | — | +6,826 | 17.0K | +67% | — |
| DM | 2022-05-05 | 2022-05-03+ | OGN | Organon & Co. | Milligan Sandra | Head of Research, Development | F - Tax | $32.36 | -2,331 | 12.1K | -16% | -$75.4K |
| D | 2022-05-03 | 2022-05-01 | OGN | Organon & Co. | Milligan Sandra | Head of Research, Development | F - Tax | $32.33 | -540 | 10.7K | -5% | -$17.5K |
| D | 2022-05-03 | 2022-05-01 | OGN | Organon & Co. | Milligan Sandra | Head of Research, Development | M - OptEx | — | +1,896 | 11.3K | +20% | — |
| D | 2022-03-02 | 2022-02-28 | OGN | Organon & Co. | Milligan Sandra | Head of Research, Development | M - OptEx | — | +10.2K | 12.3K | +473% | — |
| D | 2022-03-02 | 2022-02-28 | OGN | Organon & Co. | Milligan Sandra | Head of Research, Development | F - Tax | $37.57 | -2,941 | 9,380 | -24% | -$110.5K |
Purchase Sale Sale after option exercise All abbreviations